Hirva Mamdani, MD

Articles by Hirva Mamdani, MD

Adjuvant Durvalumab Strategy in Locally Advanced Esophageal GEJ Adenocarcinoma

January 24th 2020

Hirva Mamdani, MD, explains the rationale for conducting a safety and efficacy study of durvalumab in patients following multimodality therapy for locally advanced esophageal and gastroesophageal junction adenocarcinoma.

Latest Updated Articles

Adjuvant Durvalumab Strategy in Locally Advanced Esophageal GEJ Adenocarcinoma
Published: January 24th 2020 | Updated:

Hirva Mamdani, MD

Articles by Hirva Mamdani, MD

Adjuvant Durvalumab Strategy in Locally Advanced Esophageal GEJ Adenocarcinoma

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL

Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC

JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update

LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors

Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma